Apple (Nasdaq: AAPL) has a monster of a problem.
The maker of iPhones and iPads has roughly $137 billion of cash on its balance sheet. On paper, that looks like $137,000,000,000 — or more than the gross domestic product of Ecuador.
That doesn’t even count the money the company is raking in this quarter. It’s just the cash it has sitting in the bank right now.
This might seem like a nice problem to have… After all, an ample cash reserve is important for independence and security. But having too much cash, especially at current record-low interest rates, may be crippling Apple’s ability to grow.
For the better part of the last decade, Apple was a model of innovation and financial performance. The company enjoyed a track record of introducing sleek, game-changing products and services, including the iPod and iTunes. But it wasn’t always a smooth ride for Apple.
In 1997, Apple was in deep financial trouble. The company brought back its visi onary founder Steve Jobs. But Jobs alone couldn’t save Apple… he needed money. The only way Apple could save itself was to grovel before its arch rival Microsoft (Nasdaq: MSFT) and borrow $150 million.
Hot Healthcare Technology Companies To Buy For 2015: Green Dot Corporation (GDOT)
Green Dot Corporation operates as a bank holding company. It offers general purpose reloadable prepaid debit cards, and cash loading and transfer services in the United States. The companys products include Green Dot MasterCard, Visa-branded prepaid debit cards, and various co-branded reloadable prepaid card programs; Visa-branded gift cards; and MoneyPak and swipe reload proprietary products that enable cash loading and transfer services through its Green Dot Network. Its Green Dot Network enables consumers to use cash to reload its prepaid debit cards or to transfer cash to any of the companys Green Dot Network acceptance members, including competing prepaid card programs, and other online accounts. The company markets its cards and financial services to banked, underbanked, and unbanked consumers. Green Dot Corporation offers its products and services through retail distributors, including mass merchandisers, drug store and convenience store chains, and supermarket chains; the Internet; and relationships with other businesses. Its prepaid debit cards and prepaid reload services are available to consumers at approximately 60,000 retail locations nationwide and online at greendot.com. The company was formerly known as Next Estate Communications, Inc. and changed its name to Green Dot Corporation in October 2005. Green Dot Corporation was incorporated in 1999 and is headquartered in Pasadena, California.
- [By WWW.DAILYFINANCE.COM]
With all the warnings about scams collecting money from victims using Green Dot (GDOT) Money Paks or other reloadable debit cards, or a money transfer service like Western Union (WU) or MoneyGram, crooks have now turned to faking transactions on a site known for being legit — PayPal. The Federal Trade Commission is warning consumers about a new scam that tries to fool online sellers into using phony PayPal sites. The targets of the scam are typically people selling things online that have significant value, like a car or a boat. After the item is posted for sale, the FTC said an email will come from someone who says they will pay the full price. The conditions: The transaction must be immediate and it payment will be sent by PayPal. “What’s really going on? A ruse to steal your personal information, money or merchandise,” the FTC said. Two Ways to Scam You In one scenario, if you don’t have a PayPal account, the “buyer” will send you a link to set one up. The FTC urges consumers to not follow links sent by email. Anyone who wants to set up a PayPal account can do so by going to PayPal.com. In another scenario, if you do have a PayPal account, the “buyer” says the payment has been sent. You’re told to check your email where you’ll be notified that not only has the supposed buyer paid, but he accidentally sent way too much money. So, you’ll have to send back the extra by using — wait for it — a money transfer service like Western Union or MoneyGram. The problem is that no money was sent. So, if you wire money, you won’t be sending extra, you’ll just be sending your own. What You Should Do Instead The way to check to see if a payment has been made is not through an email confirmation, the FTC said. Before you ship any item or decide you have been paid, don’t rely on an email or by following links. Log directly into PayPal to see if the payment is in your account. And, the FTC warned, when anyone claims they’ve accidentally overpaid you, it should set off
- [By WWW.DAILYFINANCE.COM]
Prepaid cards that can be loaded with cash and used like debit cards are the new payment form of choice for scammers, replacing the classic method of asking victims to send money via a wire transfer service like Western Union (WU) or Moneygram (MGI). The most common vehicle is the Green Dot (GDOT) MoneyPak, which is available nearly everywhere and works just like a wire transfer. Once money is transferred via MoneyPak, it’s gone without a trace. But if you’ve been victimized by a scam, “gone without a trace” is not what you want to hear. You want to hear: “Hi, this is Green Dot customer service. Of course we can help you get your money back.” And that, according to the FBI, is just what a new crop of scam websites are doing: Pretending to provide customer service for MoneyPak, with phone numbers that actually lead to con artists aiming to re-scam the victims of earlier scams. The FBI’s Internet Crime Complaint Center reports that it has received a large number of complaints about this new fraud technique. Typically, the victim is either someone trying to get a refund of what’s on their card, or someone seeking help after they’ve been robbed in a scam involving a MoneyPak card, the FBI said. Seeking Refunds or Help, but Being Victimized Again In the refund version of the scam, the FBI said the crooks will ask for both the MoneyPak card number and either a credit card or checking account number, supposedly so a refund can be processed. Instead, the crooks now have all the information they need to use the victim’s account to load the card, and then drain it. The victim variation targets those who have already had money stolen from them using a MoneyPak card. The phony customer service representative will explain to the caller that to get the lost funds put back on the card, they’ll have to first load the same amount of cash on the card again from their own account, because “reloading is the only way to process the refund.” “In most complaints, victims are gi
Hot Healthcare Technology Companies To Buy For 2015: Alico Inc. (ALCO)
Alico, Inc., through its subsidiaries, operates as a land management company in central and southwest Florida. It involves in harvesting, hauling, and marketing citrus, as well as purchasing and reselling citrus fruit; cultivating citrus trees; and cultivating raw sugarcane for sale. The company also engages in producing and selling beef cattle, feeding cattle, and replacement heifers to packing and processing plants and contract cattle buyers, as well as through local livestock auction markets. In addition, it grows, harvests, and sells vegetables for wholesale; produces sod; sells native plants and trees for landscaping purposes; and subdivides, develops, and sells real estate property. Further, the company involves in rock and sand mining; and rents land on a tenant-at-will basis for grazing, farming, oil exploration, and recreational uses. Additionally, it engages in the planning and strategic positioning of company owned land, and negotiating and renegotiating sales c ontracts. As of September 30, 2010, Alico owned approximately 139,607 acres of land located in the Collier, Glades, Hendry, Lee, and Polk counties. The company was founded in 1960 and is based in Fort Myers, Florida.
- [By John Udovich]
Last Friday, small cap Farmland Partners Inc (NYSEMKT: FPI) had an IPO to join Gladstone Land Corp (NASDAQ: LAND), Alico, Inc (NASDAQ: ALCO) and Limoneira Company (NASDAQ: LMNR) as the latest option for retail investors seeking a way to invest in American farmland. After all, there is that old quote attributed to Mark Twain: “Buy land, they’re not making it anymore.” Moreover, February Wall Street Journal article noted that From 2009 to mid-2013, average prices for agricultural land in the US rose by half while in Iowa, Nebraska and some other Midwest farm states, prices more than doubled. However, the same article noted that there is mounting evidence that the farmland boom is fizzling out as farmland prices in Iowa fell 3% over the second half of last year and those in Nebraska fell 1%. The good news though is that today’s agricultural sector looks markedly different than it did during the last farmland bust back in the early 1980s while Greyson Colvin, the managing partner at investment manager Colvin & Co. (which owns about 7,000 acres of farmland), was quoted as saying: “We think this next 12 months is going to be the best window we’ve had in the past five years [to invest in farmland].”
- [By Marc Bastow]
Agribusiness and land management company Alico (ALCO) raised its quarterly dividend 50% to 12 cents per share, payable on Jan. 14, 2014 to shareholders of record as of Dec. 31, 2013.
ALCO Dividend Yield: 1.11%
Hot Healthcare Technology Companies To Buy For 2015: Sourcefire Inc.(FIRE)
Sourcefire, Inc. provides intelligent Cybersecurity technologies to commercial enterprises and government agencies worldwide. The company?s network security products include Sourcefire appliances for detecting, blocking, and analyzing network traffic; Sourcefire IPS to examine network packets for threats; Sourcefire NGIPS to discover the characteristics and vulnerabilities of computing devices communicating on a network; Sourcefire NGIPS with Application Control to provide granular control of applications; Sourcefire NGFW that includes application control and firewall capabilities; and Sourcefire SSL Appliance, which decrypts SSL traffic for inspection by network security appliances. It also offers FireAMP, a malware protection solution that uses data analytics to discover, understand, and block malware outbreaks; and Sourcefire Defense Center that provides application programming interfaces to interoperate third-party systems, such as firewalls, routers, log management, s ecurity information event management, trouble ticketing, patch management systems, and other technologies. In addition, the company provides Sourcefire Virtual Appliance, an application to inspect communications between different virtual machines; Sourcefire Virtual Defense Center, which provides central management, event analysis, and reporting services; Snort, a traffic inspection engine used in intrusion prevention system; ClamAV, an open source anti-malware product; and Razorback, an open-source project that addresses threat detection and protection. Further, it provides customer support, professional, and education and certification services. The company serves financial institutions, defense contractors, health care providers, IT companies, telecommunication companies, and retailers, as well as national, state, and local government agencies. Sourcefire, Inc. was founded in 2001 and is headquartered in Columbia, Maryland.
- [By Holly LaFon]
Sourcefire Inc. (3.0%) (FIRE – $75.92 – NASDAQ) (FIRE), based in Columbia, MD, provides cybersecurity technologies – both hardware and software – to enterprises and government agencies worldwide. On July 23, 2013, Cisco announced it would acquire Sourcefire for $76.00 cash per share. The $2.7 billion merger currently has all required regulatory approvals. The shareholder vote is scheduled on October 7, and the deal should close shortly thereafter.
- [By Eric Volkman]
Sourcefire (NASDAQ: FIRE ) now has a new leader at the top. The company has named John Becker as its CEO, effective immediately. Becker replaces the IT security company’s founder and interim CEO, Martin Roesch.
- [By Evan Niu, CFA]
What: Shares of Sourcefire (NASDAQ: FIRE ) were on fire today, enjoying gains as great as 15%, after the company reported earnings.
So what: Revenue in the first quarter came in at $56.2 million, which resulted in non-GAAP earnings per share of $0.11. Those figures represent misses on both top and bottom lines, as analysts were expecting sales of $57.4 million and adjusted earnings of $0.12 per share.
- [By Michael A. Robinson]
Chambers is using some of that cash to flesh out Cisco’s franchise. He recently agreed to buy cybersecurity firm Sourcefire Inc. (Nasdaq: FIRE) for $2.7 billion. Last week, Chambers announced Cisco is buying WHIPTAIL, a maker of solid-state computer memory systems, for roughly $415 million.
Hot Healthcare Technology Companies To Buy For 2015: Huntington Ingalls Industries Inc. (HII)
Huntington Ingalls Industries, Inc. designs, builds, overhauls, and repairs ships primarily for the U.S. Navy and Coast Guard. It offers nuclear-powered ships, such as aircraft carriers and submarines; and non-nuclear ships, including surface combatants, expeditionary warfare/amphibious assault, coastal defense surface ships, and national security cutters, as well as engages in the refueling and overhaul, and inactivation of nuclear-powered ships. The company also operates as a full-service systems provider for the design, engineering, construction, and life cycle support of major programs for surface ships; and a provider of fleet support and maintenance services for the U.S. Navy. In addition, it provides a range of support services, including fabrication, construction, equipment, and technical services, as well as product sales to commercial nuclear power plants, fossil power plants, and other industrial facilities, as well as government customers. The company is based in Newport News, Virginia.
- [By Victor Selva]
The firm is currently Zacks Rank # 2 – Buy, and it also has a longer-term recommendation of “Neutral.” For investors looking for a better Zacks Rank, Huntington Ingalls Industries Inc. (HII) could be the option.
- [By Louis Navellier]
Here are three under-the-radar “best of the best” stocks to buy that get a “Triple-A” from Portfolio Grader and should power your portfolio in 2014.
Huntington Ingalls (HII)
Huntington Ingalls (HII) builds and repairs ships, primarily for the U.S. Navy and the Coast Guard. Ingalls builds the giant nuclear aircraft carriers, nuclear submarines, cutters and every type of warship in between. HII also offers refueling and overhaul services for nuclear vessels.
- [By Katie Spence]
Who builds what
Both General Dynamics’ (NYSE: GD ) Bath Iron Works shipbuilding company and Huntington Ingalls Industries’ (NYSE: HII ) Ingalls Shipbuilding build the DDG 51 Aegis Destroyer, with the Navy typically buying ships from each builder.
Hot Healthcare Technology Companies To Buy For 2015: Destination XL Group Inc (DXLG)
Destination XL Group, Inc., formerly Casual Male Retail Group, Inc., incorporated in 1976, is a specialty retailer of big and tall men’s apparel with retail operations in the United States and London, England and direct businesses throughout the United States, Canada and Europe. Its direct business includes several catalogs and e-commerce sites, which supports its brands and product extensions. As of January 28, 2012, it operated 360 Casual MaleXL retail stores, 60 Casual MaleXL outlet stores, 16 DestinationXL stores and 14 Rochester Clothing stores. During the third quarter of fiscal 2011, the Company launched its new DestinationXL e-commerce site which, similar to its DXL store concept, brings all of its existing websites together, making it easier for its customer to shop the full array of product selection that it have to offer from all of its brands with the ease of one shopping cart. Full product assortments from Casual MaleXL, Rochester Clothing, ShoesXL and Livin gXL can be found at www.destinationxl.com. In addition to its e-commerce and catalog businesses, it operated 7 international Web stores serving twenty-six European countries during fiscal 2011.
Casual MaleXL Outlet
The Company’s 60 Casual MaleXL outlet stores, with their supporting direct business, B&T Factory Direct, generates approximately 12% of the Company’s business. It offers a private-label program, specifically for its Casual MaleXL outlet stores and its B&T Factory Direct businesses, which is similar to its lifestyle private label lines found in its full-price retail stores but made at lower costs and sold at lower price points for its value-oriented customers. It carries Canyon Ridge, which is similar in style to its Harbor Bay product line, 555 Turnpike, which is targeted towards its younger customers, and Fuse, a contemporary line similar in style to its Synrgy product line Traveler Technology is a traditional line similar to its Gold Series.
Casual MaleXL Retail
Th! e Casual Male business offers a selection of sportswear, dress clothing, footwear and accessories for the big and tall customer at moderate prices. Its full-price Casual Male merchandise is sold through its 360 Casual MaleXL retail stores, Casual MaleXL catalogs and e-commerce site. The majority of the Casual Male merchandise is basic or fashion-neutral items, such as jeans, casual slacks, tee-shirts, polo shirts, dress shirts and suit separates. Casual Male’s clothing has features specifically designed for its customer, such as waist-relaxer pants, stretch belts, zipper ties, wide band socks, neck-relaxer shirts and clothing with comfort-stretch technology and reinforced stress points. In addition to its many private label lines, it carry several well-known brands of merchandise including: Polo Ralph Lauren, Nautica, Geoffrey Beene, Nautica Jeans Co., Levi’s, Dockers, Calvin Klein, Reebok and
At January 28, 2012, it operate d 14 Rochester Clothing stores, located in major cities throughout the United States and one store in London, EnglandAn important element to the Company’s business is its high-end, luxury fashion apparel offered by Rochester Clothing. Its Rochester Clothing stores carry a selection of apparel, at higher price points, from branded manufacturers, such as Polo Ralph Lauren, Robert Graham, Lacoste, Facconable, DKNY, Calvin Klein, Michael Kors, Brioni, Cutter and Buck, Tommy Bahama, Tommy Hilfilger, Thomas Dean, Paul & Shark and others. The Rochester customer is able to find a range of apparel from traditional and modern sportswear to suits and accessories.
B&T Factory Direct
The Company’s B&T Factory Direct Web store enhances its existing Casual MaleXL outlet stores. The merchandise offered in its B&T Factory Direct catalogs and on its Website is a selection but similar to the merchandise that can be found in its Casual MaleXL outlet stores. In addit ion, B&T Factory Direct often features a special clearance o! pportunit! ies of product and provides opportunities of product obtained from Casual MaleXL and Rochester Clothing, offering the B&T Factory Direct customer the ability to purchase branded product.
The LivingXL business, which includes its LivingXL Web store and catalogs, specializes in the selling of selected products. The types of products sold on its Website and in its catalogs for both men and women and include chairs, outdoor accessories, travel accessories, bed and bath and fitness equipment.
Its ShoesXL Web store carries a line of men’s footwear in extended sizes, offering customers a range of footwear. The assortment on ShoesXL is a reflection of its apparel, with an assortment from moderate to luxury and from casual to formal. ShoesXL has a more than 500 styles of shoes, ranging in sizes from 10M to 18M and widths up to 5E. It carries a number of designer brands including Cole Haan, Allen Edmonds, Timbe rland, Calvin Klein, Lacoste and Bruno Magli. In addition, it has added the expanded shoe assortments within its existing Casual MaleXL and Rochester Clothing catalogs.
From the DestinationXL homepage, the customers can also search across all of its brands without having to specifically shop Casual Male versus Rochester. By searching for a shirt in their size, DestinationXL provides them product selection from all three of its concepts.
The Company offers selected Casual Male merchandise on their websites at www.Sears.com and www.Sears.ca. It operates 7 online stores for both its Casual MaleXL and Rochester Clothing brands that penetrate 26 European countries, including the U.K., Germany, France, Italy, Spain and the Netherlands. It engages GSI Commerce, Inc. (GSI) for the design, development and operations of the seven online stores. Subsequent to year end, it decided to discontinue its international Web stores includi ng terminating its contract with GSI.
The Comp! any compe! tes with Wal-Mart, J.C. Penney Company Inc, Kohl’s and Pinault-Printemps-Redoute, SA.
- [By Peter Graham]
The Q1 2014 earnings report for The Men’s Wearhouse, Inc (NYSE: MW), a potential peer of men’s apparel retailers like Destination XL Group Inc (NASDAQ: DXLG) and Jos. A. Bank Clothiers Inc (NASDAQ: JOSB), is scheduled for before the market opens on Friday. Aside from the Men’s Wearhouse earnings report, it should be said that Destination XL Group Inc reported Q1 2014 earnings on May 29th (Sales rebounded in April to offset weather impacted business) while Jos. A. Bank Clothiers Inc reported Q4 2013 earnings on April 2nd with Q1 2014 earnings expected on Friday. I should mention though that The Men’s Wearhouse is acquiring Jos. A. Bank Clothiers Inc – a deal recently approved of by the FTC. The merger creates the fourth-largest retailer of menswear, which will have $3.5 billion in pro forma sales, 1,700 stores and about 23,000 employees.
- [By John Udovich]
As we head into Black Friday and the holiday shopping season, small cap apparel retail stocks Cache, Inc (NASDAQ: CACH), Stein Mart, Inc (NASDAQ: SMRT), Pacific Sunwear of California, Inc (NASDAQ: PSUN) and Destination XL Group Inc (NASDAQ: DXLG) have the distinction of being the best performing small cap apparel retail stocks for this year (according to Finviz.com) with gains of 111.6%, 92.7%, 88.7% and 65.7%, respectively. What are these high flying small caps doing right in the apparel retail space and will they continue delivering a stellar performance for Black Friday and the all important holiday season for investors? Here is what new and existing investors and traders alike need to know or consider:
- [By Eric Volkman]
Destination XL (NASDAQ: DXLG ) results for the company’s Q1 have been released. For the quarter, sales were $93.6 million, a decline from the $95.5 million in the same period the previous year. Net income suffered a steeper fall, dropping to just over $1 million ($0.02 per diluted share) from the Q1 2012 result of $2.3 million ($0.05).
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market’s best stocks, it’s worth checking up on your companies’ free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That’s what we do with this series. Today, we’re checking in on Destination XL Group (Nasdaq: DXLG ) , whose recent revenue and earnings are plotted below.
Hot Healthcare Technology Companies To Buy For 2015: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholl y owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon’s portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
The Company’s Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented pr escription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company’s Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tu mors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chron ic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company’s Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company’s Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson’s disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
The Company’s Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon’s Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcryS of IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division’s Ophthalmic Pharmaceuticals business combines Alcon’s range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division’s Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav soluti on for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
The Company’s Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics , Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women’s health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals’ Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company’s Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world’s blood supply. Novartis Vaccines’ products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company’s influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines includ e Polioral and Quinvaxem.
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for c ompanion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
- [By Todd Campbell]
1. Regeneron Pharmaceuticals (NASDAQ: REGN ) : up 4,508% since 2005.
In 2005, Regeneron was a clinical-stage biotech company with no FDA-approved products, but it was working on Eylea, a treatment for wet stage age-related macular degeneration, or wet AMD, that had entered clinical trials in 2004. At the time, Regeneron might have caught investors’ attention because of Novartis (NYSE: NVS ) , which was awaiting FDA approval for Lucentis, its own treatment for wet AMD. Lucentis was widely expected to be a top seller, and quickly became a billion-dollar blockbuster upon winning FDA approval in 2007. Despite the halo effect from Lucentis, investors betting on Regeneron in the mid-to-late 2000s were still taking on substantial risk. After all, Regeneron was a small-cap biotech, with no sales. Moreover, Regeneron faced a significant uphill climb given that, historically, 90% of drugs in clinical trials fail. Ultimately, Regeneron overcame those odds to win FDA approval for Eylea in 2011; the drug became a major commercial success, with sales likely to hit $3 billion next year.
- [By John Udovich]
Small cap biopharmaceutical stock Vanda Pharmaceuticals Inc (NASDAQ: VNDA) surged 14.02% after announcing a settlement agreement with Novartis AG (NYSE: NVS) related to ongoing license arbitration proceedings for Fanapt, a schizophrenia treatment drug – meaning its worth taking a closer look at the stock along with large caps Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb Co (NYSE: BMY) which also have important schizophrenia drugs in their portfolios.
- [By Jayson Derrick]
Novartis (NYSE: NVS) said that its experimental heart failure drug LCZ696 will eventually generate $2 billion to $5 billion in sales. Shares gained 2.37 percent, closing at $92.35.
Hot Healthcare Technology Companies To Buy For 2015: Entegris Inc. (ENTG)
Entegris, Inc. develops, manufactures, and supplies products and materials used in processing and manufacturing in the semiconductor and other high-technology industries worldwide. It operates in three segments: Contamination Control Solutions, Microenvironments, and Specialty Materials. The Contamination Control Solutions segment offers liquid filtration products, components and systems, and gas filtration products that purify, monitor, and deliver critical liquids and gases to the semiconductor manufacturing process and similar manufacturing processes. The Microenvironments segment provides wafer and reticle handling products, wafer shipping products, and data storage products to preserve the integrity of wafers, reticles, and electronic components at various stages of transport, processing, and storage. The Specialty Materials segment offers graphite components used in semiconductor equipment; and low-temperature, plasma-enhanced chemical vapor deposition coatings for c ritical components of semiconductor manufacturing equipment used in various stages of the manufacturing process. The company sells its products primarily through direct sales force, and strategic and independent distributors to integrated circuit device manufacturers, original equipment manufacturers (OEM), gas and chemical manufacturing companies, and high-precision electronics manufacturers; and electrical discharge machining customers, glass container manufacturers, aerospace manufacturers, and biomedical implantation device manufacturers, as well as flat panel display OEMs, materials suppliers, and end users. Entegris, Inc. was founded in 1966 and is headquartered in Billerica, Massachusetts.
- [By Roberto Pedone]
One technology player that insiders are active in here is Entegris (ENTG), which develops, manufactures and supplies products and materials that are used in processing and manufacturing in the microelectronics and other high-technology industries worldwide Insiders are buying this stock into notable weakness, since shares are off by 11.8% over the last three months.
Entegris has a market cap of $1.6 billion and an enterprise value of $2 billion. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 43.4 and a forward price-to-earnings of 12.9. Its estimated growth rate for this year is 15.3%, and for next year it’s pegged at 32.4%. This is not a cash-rich company, since the total cash position on its balance sheet is $377.94 million and its total debt is $817.70 million.
A beneficial owner just bought 477,700 shares, or about $5.34 million worth of stock, at $11.19 per share.
From a technical perspective, ENTG is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $10.69 to $10.67 a share. Following that bottom, shares of ENTG have now started to uptrend and the stock is quickly moving within range of triggering a major breakout trade above some key near-term overhead resistance levels.
If you’re bullish on ENTG, then I would look for long-biased trades as long as this stock is trending above some near-term support at $11.25 a share or above those double bottom support levels and then once it breaks out above some near-term overhead resistance levels at $11.90 to $12.31 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 819,820 shares. If that breakout triggers soon, then ENTG will set up to re-test or possibly take out its next major overhead resistance level at its 52-week high of $14.05 a share.
- [By Garrett Cook]
Entegris (NASDAQ: ENTG) shares were also up, gaining 3.21 percent to $13.50 after the company lifted its second-quarter outlook.
Equities Trading DOWN
- [By Garrett Cook]
Entegris (NASDAQ: ENTG) shares were also up, gaining 2.45 percent to $13.40 after the company lifted its second-quarter outlook.
Equities Trading DOWN
- [By Vanina Egea]
ATMI supplies high performance materials, materials packaging and materials delivery systems for use in the manufacture of microelectronics devices worldwide. ATMI agreed to be acquired by Entegris (ENTG) for $1.15 billion, or $34 per share. The deal will provide a lot more of product offerings. The acquisition is expected to close during the second calendar quarter of 2014.
Hot Healthcare Technology Companies To Buy For 2015: Riverbed Technology Inc.(RVBD)
Riverbed Technology, Inc. provides solutions to the fundamental problems associated with information technology performance across wide area networks (WANs) in the United States and internationally. It primarily offers Steelhead products, which enable its customers to improve the performance of their applications and access to their data across WANs, as well as supports the riverbed services platform. The company’s Steelhead product family includes the Steelhead Mobile client software application that provides mobile workers with LAN-like access to corporate files and applications; Virtual Steelhead appliance to extend the reach of WAN optimization; Cloud Steelhead, a solution that is purpose-built for public cloud computing environments; Central Management Console that provides centralized configuration, monitoring, and control for simplifying the process of deploying and managing Steelhead products distributed across a WAN; and Interceptor appliance, which allows organiz ations to scale their WAN optimization solutions. It sells Steelhead appliances to customers ranging from small office deployments to large headquarters and data center locations. The company also offers Cascade product line, which help organizations manage, secure, and optimize the availability and performance of global applications; Stingray product line, which provides virtual application delivery control; and Whitewater gateways, designed to accelerate, de-duplicate, secure, and store backup data sets in the public cloud. It serves customers in manufacturing, finance, technology, government, architecture, engineering and construction, professional services, utilities, healthcare and pharmaceuticals, media, and retail industries. The company sells its products directly through value-added resellers and distributors, service providers, and systems integrators, as well as through its sales force. Riverbed Technology, Inc. was founded in 2002 and is headquartered in San Fra n cisco, California.
- [By Anna Prior]
Among the companies with shares expected to actively trade in Monday’s session are Citigroup Inc.(C), Riverbed Technology Inc.(RVBD) and Abbvie Inc.(ABBV)
- [By Eddie Staley]
Riverbed Technology (NASDAQ: RVBD) shares tumbled 6.77 percent to $18.97 after the company lowered its Q2 revenue forecast.
GT Advanced Technologies (NASDAQ: GTAT) was down, falling 5.92 percent to $15.10 after cautious comments by CLSA.
Hot Healthcare Technology Companies To Buy For 2015: Federated Investors Inc. (FII)
Federated Investors, Inc. is a publicly owned investment manager. The firm provides its services to individuals, including high net worth individuals, banking or thrift institutions, investment companies, pension and profit sharing plans, pooled investment vehicles, charitable organizations, state or municipal government entities, and registered investment advisors. Through its subsidiaries, it manages separate client-focused equity, fixed income, and money market mutual funds and separate client-focused equity, fixed income, and balanced portfolios. The firm invests in the public equity and fixed income markets across the globe. It invests in growth and value stocks of small-cap, mid-cap, and large-cap companies. The firm makes its fixed income investments in ultra-short, short-term, and intermediate-term mortgage-backed, U.S. Government, U.S. Corporate, high yield, and municipal securities. It employs a fundamental and a quantitative analysis to make its equity investmen ts. The firm also makes sector-focused equity investments. Federated Investors was founded in 1955 and is based in Pittsburgh, Pennsylvania with an additional office in New York, New York.
- [By Jordan Wathen]
A federation of free cash flow
Federated Investors (NYSE: FII ) also looks appealing, even though its biggest business isn’t contributing to the bottom line.
- [By Ben Levisohn]
But there are winners–and they’re any stock that’s helped by higher rates. There are mutual fund companies with big money-market fund businesses, who wouldn’t be forced to run these funds for what is essentially free. Federated Investors (FII), for instance, has jumped 2.1% to $27.99. Life insurance companies, too, are rising because they should be able to earn more on their investments. MetLife (MET), for instance, has risen 1.3% to $53.03.